Pharmacokinetic study of an iridoid glucoside: aucubin.
Aucubin, a promising hepatoprotecting iridoid glucoside, was given intravenously (iv), orally (po), intraperitoneally (ip), and hepatoportally (pv) to rats. A linear pharmacokinetic behavior was obtained after iv administation of 400-400 mg/kg of aucubin. The half-life of aucubin in the postdistributive phase (t1/2, beta), total-body plasma clearance (CLt), and volume of distribution (Vdss) were 42.5 min, 7.2 ml/min/kg, and 346.9 ml/kg, respectively, for a 40 mg/kg dose. There was no significant difference in the parameters as a reult of increasing dose. The partition coefficients of aucubin between n-octanol and buffers of pH 3.0-10.0 were low, while 18.5 +/- 1.3% of aucubin in whole blood partitioned into the blood cells. Plasma protein binding of aucubin was only 9%. The bioavailabilites of aucubin after administration at a dose of 100 mg/kg through pv, ip, and po routes were 83.5, 76.8, and 19.3%, respectively. The pH-stability profile indicated rapid degradation of aucubin at pH 1.2, 1.6, and 2.0, with degradation half-lives of 5.1, 5.8, and 14.8 hr, respectively, at 37 degrees C. Therefore, the low oral bioavailability of aucubin may be attributed to pH-instability in the gastric fluid, poor GI absorption due to low lipophilicity, and the possible metabolism in the GI mucosa and liver (so called first-pass effect).
College of Pharmacy, Seoul National University, Korea.
N J
NJ
Suh
C K
CK
Shim
M H
MH
Lee
S K
SK
Kim
I M
IM
Chang
D000818:Animals; D001682:Biological Availability; D001798:Blood Proteins / Q000378:metabolism; D004355:Drug Stability; D005960:Glucosides / Q000493:pharmacokinetics*; D057888:Iridoid Glucosides; D039823:Iridoids; D008297:Male; D011485:Protein Binding; D051381:Rats; D011919:Rats, Inbred Strains; D012995:Solubility
D001798:Blood Proteins; D005960:Glucosides; D057888:Iridoid Glucosides; D039823:Iridoids; C006650:aucubin